Physician profile
Ashlyn Gates
NPI 1487277208
$7,837.28
in general payments reported to CMS, 2019-2025
21 companies · $72.73 in 2025
The $72.73 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,985 · 2022: $2,301 · 2023: $2,358 · 2024: $1,120 · 2025: $72.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,550.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.79 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $826.75 | 2021-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $770.60 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $695.88 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $694.90 | 2021-2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $640.51 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $628.48 | 2021-2023 | Trintellix |
| Alkermes, INC. | $429.87 | 2021-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $403.01 | 2021-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $369.04 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Idorsia Pharmaceuticals US INC | $304.15 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $226.74 | 2023-2024 | Auvelity |
| Lundbeck LLC | $211.32 | 2021-2025 | Rexulti |
| Corium, LLC | $142.54 | 2021-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $139.97 | 2022-2024 | Austedo Xr, Uzedy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $52.81 | 2021-2022 | |
| Almatica Pharma LLC | $44.03 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $16.63 | 2023 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $15.61 | 2024 | Cobenfy |
| Adlon Therapeutics L.P. | $14.19 | 2021 | |
| Allergan, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlyn Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.